Sanofi has paid €120 million upfront and committed to up to €495 million more for a stake in AstraZeneca’s experimental monoclonal antibody against RSV.
Arix Bioscience has teamed up with Takeda Ventures to create and grow biotechs.
Roche is doubling down on its anti-amyloid beta antibody crenezumab with a second phase 3 Alzheimer's trial.
Advaxis has licensed its antigen delivery technology for use in Sellas’ cancer immunotherapy.
Almac Discovery and the Royal College of Surgeons in Ireland have teamed up to research the effect of ALM201 on cancer stem cells.
Ferring Pharmaceuticals is funding development of a long-duration peptide drug based on Foresee’s delivery technology.
Johnson & Johnson has unveiled a clutch of deals intended to grow its presence in the microbiome sector.
Ophthotech has started a search for ophthalmic drugs, pipeline prospects and technologies it can rebuild its business around.
Astellas has licensed a drug that could provide an alternative to surgery for tympanic membrane perforation (TMP) developed by Auration Biotech.
Heptares Therapeutics has teamed up with the University of Cambridge to discover molecules that modulate a cardiovascular target.